Genome-wide Screen of Otosclerosis

Population Biobanks: 18 Loci and Shared Heritability with Skeletal Structure

Joel T. Rämö¹, Tuomo Kiiskinen¹, Juha Karjalainen^{1,2,3,4}, Kristi Krebs⁵, Mitja Kurki^{1,2,3,4}, Aki S. 4 5 Havulinna⁶, Eija Hämäläinen¹, Paavo Häppölä¹, Heidi Hautakangas¹, FinnGen, Konrad J. Karczewski^{1,2,3,4}, Masahiro Kanai^{1,2,3,4}, Reedik Mägi⁵, Priit Palta^{1,5}, Tõnu Esko⁵, Andres Metspalu⁵, 6 Matti Pirinen^{1,7,8}, Samuli Ripatti^{1,2,7}, Lili Milani⁵, Antti Mäkitie⁹, Mark J. Daly^{1,2,3,4,10}, and Aarno 7 Palotie^{1,2,3,4} 8 9 1. Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of 10 Helsinki, Helsinki, Finland 2. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, 11 12 Massachusetts, USA 13 3. Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, 14 USA 15 4. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA 16 5. Estonian Genome Center, University of Tartu, Tartu, Estonia, Institute of Molecular and Cell Biology, 17 University of Tartu, Tartu, Estonia 18 6. Finnish Institute for Health and Welfare, Helsinki, Finland 19 7. Department of Public Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland 20 8. Department of Mathematics and Statistics, Faculty of Science, University of Helsinki, Helsinki, Finland 21 9. Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and HUS Helsinki 22 University Hospital, Helsinki, Finland 23 10. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA 24 25 Corresponding author: Aarno Palotie, MD PhD, University of Helsinki, Tukholmankatu 8, FI-00290 26 Helsinki, Finland. Email aarno.palotie@helsinki.fi

27

1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

in

Abstract 28

29

30 Otosclerosis is one of the most common causes of conductive hearing loss, affecting 0.3% of the population. It typically presents in adulthood and half of the patients have a positive family history. 31 32 The pathophysiology of otosclerosis is poorly understood and treatment options are limited. A previous genome-wide association study (GWAS) identified a single association locus in an intronic 33 34 region of *RELN*. Here, we report a meta-analysis of GWAS studies of otosclerosis in three population-35 based biobanks comprising 2,413 cases and 762,382 controls. We identify 15 novel risk loci (p < 5*10⁻⁸) and replicate the regions of *RELN* and two previously reported candidate genes (*TGFB1* and 36 MEPE). Implicated genes in many loci are essential for bone remodelling or mineralization. 37 38 Otosclerosis is genetically correlated with height and fracture risk, and the association loci overlap with severe skeletal disorders. Our results highlight TGF^{β1} signalling for follow-up mechanistic 39 40 studies.

Introduction 41

42 Otosclerosis is one of the most common causes of conductive hearing loss. It is a heritable disorder typically characterized by disordered bone growth in the middle ear.^{1,2} In classic otosclerosis, due 43 to fixation of the footplate of the stapes bone, the conduction of sound through the ossicular chain 44 to the inner ear is interrupted. The pathogenesis of otosclerosis is poorly understood, and 45 therapeutic options are mostly limited to hearing aids, prosthesis surgery and cochlear implants.³ 46

47 Clinical otosclerosis has an estimated prevalence of 0.30% to 0.38% in Caucasian populations.⁴ Histologic otosclerosis without clinical symptoms is more frequent, with bony overgrowth observed 48 in as many as 2.5% of temporal bone autopsy specimens.⁵ Symptomatic otosclerosis most 49 frequently occurs in working-age individuals between the second and fifth decades.^{6,7} Initial 50 51 manifestation is often limited to one ear, but eventual bilateral disease is observed in 70-80% of cases.6,7 52

Otosclerosis is highly familial, with a positive family history reported for 50-60% of cases.^{8,9} Based 53 on segregation patterns, early studies classified otosclerosis as an autosomal dominant disease with 54 reduced penetrance.⁹⁻¹¹ However, efforts to identify causative genes have produced inconsistent 55 results, with insufficient evidence for most candidate genes.^{12,13} A genome-wide association study 56 (GWAS) including a total of 1,149 otosclerosis patients identified intronic risk variants within the 57 gene encoding Reelin (RELN) in European populations.^{14,15} However, the potential biological 58 function of Reelin and the role of other genes remain unknown. 59

60 Here, we report to our knowledge the largest GWAS of otosclerosis including a total of 2,413 cases and 762,382 controls from three population-based sample collections: the Finnish FinnGen study, 61 the Estonian Biobank (EstBB), and the UK Biobank (UKBB). We identify 15 novel GWAS loci, and 62 replicate associations in the regions of RELN and two previously reported candidate genes, TGFB1 63 64 and *MEPE*.¹⁴⁻¹⁹ Several discovered loci harbor genes involved in the regulation of osteoblast or 65 osteoclast function or biomineralization. We also demonstrate that otosclerosis is genetically 66 correlated with common and rare skeletal traits.

Results 67

Identification of otosclerosis cases based on electronic health records 68

69 Based on International Clasification of Diseases (ICD) diagnosis codes (versions 8, 9 and 10), we 70 identified a total of 2,413 otosclerosis cases in the three biobanks, including 1,350 cases in FinnGen, 713 in EstBB and 353 in UKBB, for cohort prevalences of 0.64%, 0.52%, and 0.08%, respectively 71 72 (Table 1). A total of 762,382 individuals had no ICD-based diagnosis of otosclerosis and were 73 assigned control status. A proportion of otosclerosis patients undergo stapes procedures, which reflect disease severity and the validity of the ICD-based diagnoses. Stapes procedures were 74 registered for 544 (40.3%) otosclerosis cases in FinnGen and for 161 (22.6%) otosclerosis cases in 75 76 EstBB. Among all 1,350 individuals diagnosed with otosclerosis in FinnGen, five (0.37%) had a 77 diagnosis of osteogenesis imperfecta (representing 12% of all 41 individuals with osteogenesis 78 imperfecta), and none had a diagnosis of osteopetrosis.

79 Genomic loci associated with otosclerosis in each cohort

80 In case-control GWASs within the individual cohorts, we observed ten loci associated with otosclerosis at genome-wide significance ($p < 5*10^{-8}$) in FinnGen, four in UKBB and one in EstBB 81 (Supplementary Data 1; Supplementary Data 2). Two loci were associated in both FinnGen and 82 83 UKBB: A chromosome 11 locus tagged by the lead variants rs11601767 and rs144458122, 84 respectively, and a chromosome 17 locus upstream of FAM20A tagged by rs11868207 and 85 rs11652821. Among all FinnGen lead variants, six were associated with otosclerosis at nominal significance (p < 0.05) in UKBB and five were associated with otosclerosis in EstBB. All three UKBB 86 87 lead variants were nominally significant in FinnGen. The only genome-wide significant variant in EstBB (rs78942990, $p = 4.2 \times 10^{-8}$, MAF = 2.0%) was not associated with otosclerosis in either 88 89 FinnGen or UKBB at nominal significance level.

90 We calculated pairwise genetic correlation rg using summary statistics from the different cohorts with the cross-trait LD Score Regression.^{20,21} R_g between FinnGen and UKBB was 1.04, indicating 91 similar genetic effects between the two cohorts.²² The calculation of r_g was not feasible for EstBB 92 due to a negative heritability estimate (observed scale $h^2 = -0.0063$ [S.E. 0.003]), likely reflecting 93 94 modest polygenic signal in the cohort. However, as the effect estimates for lead variants were

95 largely concordant between the three cohorts (Supplementary Data 2), we proceeded with a fixed96 effects meta-analysis.

97 18 significant loci in the meta-analysis of summary statistics

In the meta-analysis of all three cohorts (including a total of 2,413 cases and 762,382 controls) we identified 1,257 variants associated with otosclerosis at the genome-wide significance level (p < $5*10^{-8}$). The genomic inflation factor calculated from the meta-analysis *p*-values was not significantly elevated (λ_{GC} =1.03). The univariate LD Score regression intercept was closer to 1.0 at 1.016 (S.E. 0.009), indicating that part of the elevation in λ_{GC} reflected true additive polygenic effects and not spurious associations from population stratification or cryptic relatedness.²¹

The significant variants in the meta-analysis clustered in a total of 18 loci (regions at least 500kb apart) (Figure 1; Table 2; Supplementary Data 3; Supplementary Data 4), including the previously reported *RELN* locus and 17 loci not previously reported in a GWAS study of otosclerosis.¹⁴ All lead variants in the 18 meta-analysis loci were common with a cross-cohort effect allele frequency (EAF) of at least 16% (Table 2). In two loci the closest genes (*MEPE* and *TGFB1*) have been implicated in candidate gene studies; to our knowledge, the remaining 15 loci have not been characterized in association with otosclerosis.¹⁵⁻¹⁹

111 Characterization of the potential susceptibility loci for otosclerosis

112 Coding variation

The lead variant in the chromosome 3 locus, rs4917 T>C, is a missense variant in the exon 6 of AHSG 113 (EAF = 64%, OR = 0.83 [0.78-0.88], $p = 2.3*10^{-9}$). The variant results in a methionine to threonine 114 115 conversion and is predicted to be tolerated/benign by the SIFT and PolyPhen algorithms with a scaled CADD score of 9.9. However, it has been reported as a splicing quantitative trait locus (sQTL) 116 for AHSG in the liver in the GTEx v8 database ($p = 1.1 \times 10^{-7}$).²³ Among all 1,257 variants which 117 118 reached genome-wide significance in the meta-analysis, we identified no high-impact variants. Seven missense variants were significantly associated with otosclerosis (Supplementary Data 5): 119 120 rs1193851 C>G in PCNX3, rs11544832 in YIF1A, rs7990383 G>A in COL4A2, rs7990383 C>A in IRX5, 121 rs4918 G>C in AHSG, rs2229642 C>G in ITPR3, and rs4713668 in IP6K3. Rs4713668 (EAF = 0.48, OR = 1.19 [1.12-1.26], $p = 8.8 \times 10^{-9}$ is classified as deleterious and benign by the SIFT and PolyPhen 122

123 algorithms, respectively, with a scaled CADD score of 19.9. All other missense variants are classified 124 as tolerated or benign.

125 In the chromosome 4 locus near the MEPE gene, the rare frameshift variant rs753138805 (EAF 0.3% in controls and 1.3% in cases) was the lead variant in the GWAS in FinnGen, but was not included in 126 127 the meta-analysis due to poor imputation quality in EstBB (Imputation information score 0.28) and 128 non-inclusion in UKBB genotype data. The rs753138805 variant was strongly associated with 129 otosclerosis in FinnGen (OR = 18.9 [95% CI 8.05-44.4]; $p = 1.5*10^{-11}$). The variant is 2.4-fold enriched in Finnish compared with non-Finnish Europeans based on sequence data in the Genome 130 Aggregation Database.²⁴ We validated the imputation of the variant within the Migraine Family 131 subcohort of FinnGen. Among 65 individuals determined as heterozygous for rs753138805 by 132 imputation, we confirmed the genotype by Sanger sequencing in 56 individuals (86%) and in all five 133 predicted carriers of the reference allele examined as controls. 134

135 Finally, based on linkage disequilibrium in the FinnGen cohort, we examined 988 variants (including 136 those with AF < 0.001) in high LD (r > 0.6) with the lead variants from the meta-analysis, but observed no additional protein-altering variation. 137

Intronic and intergenic variation 138

139 The lead variants were intronic in seven loci. In the locus on chromosome 7, the strongest 140 association was observed for variants in the second and third introns of RELN concordant with previous GWA studies (Supplementary Data 4).^{14,15} In the locus on chromosome 19, the association 141 signal overlapped with several genes including TGFB1, AXL, HNRNPUL1 and CCDC97, with the most 142 143 significant association for the intronic TGFB1 variant rs8105161 (EAF = 16%, OR = 0.8 [0.74-0.86], p = $1.76*10^{-8}$). In chromosome 20, the associated variants were located in the first intron of EYA2. In 144 two of the significant loci, the associated variants were tightly clustered in the region of antisense 145 146 genes: COL4A2-AS2 and an intronic region of COL4A2 in chromosome 13, and STX-17-AS1 in 147 chromosome 19.

The two variants most significantly associated with otosclerosis on choromosome 14, rs1951391 148 (EAF = 33%, OR = 1.38 [1.28-1.49], p = 7.0*10⁻¹⁷) and rs62007683 G>T (EAF = 33%, OR = 1.37 [1.27-149

1.47], $p = 3.2*10^{-16}$), were both located in the same intronic region of *MARK3*. In the association 150

- It is made available under a CC-BY-NC-ND 4.0 International license.
- locus on chromosome 6, an apparent association haplotype block spanned the entire *SUPT3H* gene and the first exon and first intron of the *RUNX2* gene; the lead variant rs13192457 (EAF = 44%, OR $= 1.25 [1.17-1.34], p = 2.3*10^{-10}$) is located in an intronic region of *SUPT3H*.

154 Fine-mapping of the association loci

To identify the most likely causal variants in the otosclerosis association loci, we performed a fine-155 mapping analysis in FinnGen using the FINEMAP software (v1.4).²⁵ We analyzed ten loci that reached 156 genome-wide significance in the meta-analysis and had suggestive evidence of association in 157 158 FinnGen ($p < 1*10^{-6}$). The number of variants in the resulting credible sets ranged from three (for the chromosome 4 locus near MEPE) to 4,604 reflecting high uncertainty (Supplementary Data 6). 159 160 In the chromosome 4 locus, the MEPE frameshift variant rs753138805 was the most likely causal 161 variant (probability = 66%). In the chromosome 17 locus upstream of FAM20A, the credible set 162 included nine variants, with the most likely causal variants being rs11868207 (probability = 52%, AF = 23.6%, OR = 1.39 [1.29-1.49], p = $2.1*10^{-18}$) and rs8070086 (probability = 32%, AF = 23.6%, OR = 163 1.39 [1.29-1.49], $p = 1.8 \times 10^{-18}$). 164

165 Gene and gene set analysis

166 In a gene-based analysis using MAGMA, a total of 62 genes were significantly associated with 167 otosclerosis ($p < 2.6*10^{-6}$) (Supplementary Data 7). The gene-based associations were significantly 168 enriched ($p < 4.9*10^{-6}$) for the following gene sets based on gene ontology terms: COLLAGEN TYPE IV 169 TRIMER ($p = 4.1*10^{-7}$), BASEMENT MEMBRANE COLLAGEN TRIMER ($p = 3.7*10^{-7}$), TRANSFORMING GROWTH 170 FACTOR BETA RECEPTOR ACTIVITY TYPE I ($p = 1.7*10^{-6}$), POSITIVE REGULATION OF CHOLESTEROL METABOLIC 171 PROCESS $p = 7.9*10^{-7}$), and BIOMINERALIZATION ($p = 2.2*10^{-6}$).

Following the identification of a genome-wide significant association signal overlapping with the 172 *TGFB1* gene and gene-set association with type I TGFβ receptor activity, we examined other genes 173 involved in TGFβ1 signalling for subthreshold association signals (Supplementary Data 8).²⁶ We 174 observed a trend towards association in the TGFBR1 locus but not the TGFBR2 locus. The lead 175 variant in the *TGFBR1* locus, rs11386616 C>CG (EAF = 24%, OR = 1.18 [1.1-1.26], *p* = 2.0*10⁻⁶) is eQTL 176 177 for *TGFBR1* in whole blood in the GTEx database (NES = -0.12, $p = 2.3*10^{-13}$). The *TGFBR1* gene was 178 also significantly associated with otosclerosis in the gene-based analysis using MAGMA ($p = 1.8^{\circ}10^{\circ}$ ⁶). Within the regions coding for the SMAD proteins that function as the main signal transducers of 179

the TGFβ superfamily, we observed modest and nonsignificant association signals near *SMAD3* (intronic lead variant rs7163381 A>G [AF= 75%, OR = 0.8 [0.80-0.86], $p = 1.0*10^{-5}$]) and in the region near *TGFBI* (coding for transforming growth factor-beta-induced) and *SMAD5* (lead variant: rs17169386 T>C; EAF = 0.012, OR = 2.05 [1.43-2.95], $p = 1.3*10^{-4}$).

184 Associations with gene expression and splicing

We examined the association of lead variants with tissue-specific gene expression in the GTEx v8 database.²³ Among 18 lead variants, 11 variants were eQTL in at least one tissue at the 5% FDR cutoff provided by the GTEx project (Supplementary Data 11).²³ The 11 variants were eQTL for a total of 53 genes in 43 tissues and in addition, seven lead variants were sQTL for a total of 22 genes in 42 tissues (Supplementary Data 12). Eleven genes (*TGFB1, CKB, RUNX2, AHSG, TPBG, CLCN7, SPP1, PKD2, NEAT1, LTBP3,* and *ITPR3*) have been implicated in bone metabolism or skeletal disorders, and are described in more detail in the Discussion section.

192 The eQTL and sQTL signals suggest a regulatory role for many of the identified otosclerosis 193 susceptibility variants. In several loci, the lead variant was associated with the expression or splicing 194 of multiple genes. In the chromosome 14 locus characterized by an association haplotype block 195 spanning MARK3 and CKB, the lead variant rs1951391 T>C (EAF = 33%, OR = 1.38 [1.28-1.49], p = 196 7.0*10⁻¹⁷) was associated with the expression of both MARK3 (eQTL for 20 tissues and sQTL for 4 tissues) and CKB (eQTL for 7 tissues and sQTL for 8 tissues); the variant was also eQTL for nine and 197 sQTL for five other genes in close proximity. In the chromosome 6 locus with an association block 198 199 overlapping SUPT3H and part of RUNX2, the lead variant rs13192457 (EAF = 44%, OR = 1.25 [1.17-1.34], $p = 2.3*10^{-10}$ was eQTL for SUPT3H in several tissues (e.g. NES = 0.2 in cultured fibroblasts; p 200 = 9.1*10⁻⁸) and an sQTL for *RUNX2* in testes (NES = -0.47, $p = 7.5*10^{-15}$). In the chromosome 6 locus 201 near *IP6K3*, the lead variant rs9469583 (EAF = 58%, OR = 1.22 [1.15-1.3], $p = 2.1*10^{-10}$) was most 202 strongly associated with the expression (normalized expression score [NES] = -0.7, $p = 8.2*10^{-30}$ in 203 pancreas tissue) and splicing (NES = 0.86 in skeletal muscle, $p = 1.1*10^{-72}$) of *IP6K3*; however, the 204 205 variant was also eQTL and sQTL for several other genes, including ITPR3, UQCC2 and BAK1.

We also sought to identify variants simultaneously associated with reduced susceptibility for otosclerosis and reduced gene expression, as such genes could represent targets for therapeutic inhibition. The intronic rs8105161 lead variant in *TGFB1* was associated with protection from

otosclerosis (OR = 0.8 [0.74-0.86], $p = 1.8*10^{-8}$) and reduced expression of *TGFB1* in adrenal glands 209 (NES = -0.76, $p = 1.3 \times 10^{-19}$) and cultured fibroblasts (NES = -0.097, $p = 1.1 \times 10^{-4}$). In the chromosome 210 13 locus, in which the association signal clustered in the region of COL4A2-AS2 (COL4A2 antisense 211 2) within the COL4A2 gene, the lead variant rs9559805 (OR = 0.82 [0.77-0.87] for otosclerosis, p = 212 $3.4*10^{-11}$) was associated with reduced expression of both COL4A2-AS2 (NES = -0.17 in the 213 muscularis layer of the esophagus, $p = 3.5*10^{-6}$) and COLA42 (NES = -0.16, $p = 8.3*10^{-5}$ in 214 subcutaneous adipose tissue). 215

Replication of previous otosclerosis candidate genes 216

217 Candidate genes

218 As two of the genome-wide significant loci from the meta-analysis overlapped with candidate genes (TGFB1 and MEPE), we also examined the association signals in the regions of other candidate genes 219 220 (Supplementary Data 9; Supplementary Data 10). Nine candidate variants were included in the meta-analysis. Four previously reported susceptibility variants in or near the COL1A1 gene were 221 222 associated with otosclerosis at nominal significance in the meta-analysis, but only the upstream gene variant rs11327935 GA>G (EAF = 18%, OR = 1.11 [1.03-1.2], p = 7.3*10⁻³) was nominally 223 significant after multiple correction (OR = 1.12 [1.04-1.21], p = 0.0041).²⁷⁻²⁹ None of the previously 224 reported susceptibility variants in SERPINF1 were included in the current meta-analysis.^{13,30} 225 Observable candidate variants in BMP2 and BMP4 were not significant in the meta-analysis.³¹ 226 227 However, we observed a significant association approximately 300kb upstream of BMP2 228 overlapping the long non-coding RNA CASC20. The lead variant in this locus, rs2225347 A>T (EAF = 42%; OR = 0.82 [0.76-0.88]; $p = 6.2*10^{-8}$), is not reported as eQTL or sQTL for *BMP2* or any gene in 229 the GTEx v8 database.²³ 230

Linkage loci 231

232 Among published linkage loci, one (OTSC7, 6q13–16.1) has been narrowed to a region containing only 12 candidate genes.³² In this region, we observed a trend towards association for variants near 233 234 the gene CD109, with the lowest p-value for the intronic CD109 variant rs10805974 G>C (AF= 36%, OR = 1.16 [1.09-1.23], p = 3.4*10⁻⁶). CD109 was significantly associated with otosclerosis in the gene-235 based analysis using MAGMA ($p = 1.2*10^{-8}$). 236

237 Further associations with the 18 otosclerosis lead variants

238 Phenome-wide association studies

239 To assess pleiotropic effects of genetic risk factors to otosclerosis, we first examined the phenomewide associations of the 18 lead variants from the meta-analysis with a total of 2419 traits in UKBB 240 241 and 2925 traits in FinnGen. Six lead variants were associated with standing height, and five with heel 242 bone mineral density (BMD) in UKBB ($p < 2.1*10^{-5}$) (Supplementary Data 13). The intronic MARK3 lead variant rs1951391 was associated with forearm fractures in FinnGen ($p = 3.8*10^{-6}$) and the 243 rs753138805 frameshift variant in *MEPE* was associated with lower leg fractures ($p = 3.8*10^{-6}$). 244

245 **GWAS** Catalog

246 Among the 18 lead variants, three were reported in the GWAS Catalog as being associated with either height, BMD or BMI-adjusted waist-hip ratio (Supplementary Data 13).³³ Overall, among all 247 the 1,257 genome-wide significant variants associated with otosclerosis in our meta-analysis, 62 248 variants have been reported to be associated with a total of 45 traits (Supplementary Data 14). Eight 249 250 loci have been associated with BMD, four with height, and two with osteoarthritis. Variants 251 associated with increased risk of otosclerosis were most often associated with increased height and 252 decreased BMD. Additionally, in the chromosome 8 locus near the EIF3H gene, an intergenic variant 253 associated with otosclerosis at genome-wide significance (rs13279799, OR = 0.77 [0.71-0.83]; p = 254 2.8*10⁻¹¹) has been previously associated with ossification of the longitudinal ligament of spine, a rare form of heterotopic ossification.³⁴ 255

256 Shared heritability

257 To interrogate shared heritability between the traits, we calculated pairwise genetic correlations (rg) using summary statistics from the otosclerosis meta-analysis and published large GWA 258 259 studies.^{20,35,36} Otosclerosis was genetically correlated with fracture risk ($r_g = 0.24$ [S.E. 0.08], p =0.0034) and height (r_g = 0.10 [S.E. 0.04], p = 0.0177), but not with BMD (r_g = -0.088 [S.E. 0.056], p = 260 0.12). 261

262 **Discussion**

Although otosclerosis is highly heritable its genetic background is still poorly understood. Previous studies have reported one GWAS locus (*RELN*), while results for candidate genes have been inconclusive. Here, we identify 18 loci associated with otosclerosis, of which 15 are novel. We also replicate the *RELN* locus and two candidate gene loci – *TGFB1* and *MEPE*. These results offer further insights to disease pathophysiology.

We confirm a polygenic basis to otosclerosis and identify loci harbouring potentially causative genes
 involved in the regulation of bone structure. Earlier studies assumed a dominant inheritance, but
 the inability to map otosclerosis to one or a few high-impact genes has suggested a complex nature.
 Many etiologies to otosclerosis have been proposed, including differences in TGFβ, parathyroid
 hormone or angiotensin II signalling, alterations in collagen type I, inflammation, viral disease, and
 autoimmunity.³⁷

274 A considerable number of association loci are associated with severe skeletal disorders (Table 3). Disordered or heterotopic bone growth is a common feature e.g. in diaphyseal dysplasia (caused by 275 276 mutations in TGFB1), osteopetrosis subtypes (caused by mutations in CLCN7), and ossification of 277 the posterior longitudinal ligament of spine (GWAS signal for rs13279799 in the chromosome 8 locus). Otosclerosis presents later in adulthood and represents a more limited and common 278 279 phenotype compared with severe skeletal dysplasias. Shared heritability with height and 280 appendicular fracture risk across the genome also suggests more cumulative effects on the regulation of bone growth and remodeling. 281

The effects on bone growth and remodeling are likely mediated by several pathways. The known biological functions of many putative risk genes in otosclerosis association loci include regulation of osteoblasts – the cells responsible for bone formation – and osteoclasts – responsible for the breakdown of bone, either through effects on cell differentiation or function (Table 3). Some genes (*AHSG*, *IRX5*, and *MEPE*) are also directly involved in biomineralization, and *AHSG* and the candidate gene *MEPE* have been reported to have dual roles in the regulation of mineralization and osteoclast or osteoblast cell lineages.

289 Recently, Shrauwen and colleagues proposed a model of otosclerosis in which increased bone 290 turnover results from mutations ablating two functional motifs of MEPE, leading to both accelerated osteoclast differentiation and enhanced mineralization and thus increased bone turnover.³⁸ In 291 contrast with otosclerosis, they observed frameshift mutations ablating only one functional motif 292 293 of *MEPE* in individuals with a severe craniofacial defect with thickening of the skull, potentially reflecting an unopposed increase in mineralization. Here, we replicate at genome-wide significance 294 295 an association between otosclerosis and a frameshift mutation that is likely to ablate both functional 296 motifs in MEPE. Reflecting a systemic effect on the skeleton, the rs753138805 variant is also 297 associated with increased leg fracture risk, similarly to an unpublished study in the Norwegian HUNT cohort.39 298

Several genes in the susceptibility loci converge on Transforming growth factor beta-1 (TGFβ1) signalling pathways. *TGFB1* has long been proposed as a susceptibility gene for otosclerosis, but the quality of the supporting evidence has been relatively weak.^{15-18,28,40} Here, for the first time, we report an association at the *TGFB1* locus at genome-wide significance, with the strongest association for the intronic variant rs8105161. The significance of TGFβ1 signalling is supported by gene set enrichment and analysis of other loci.

305 TGF β 1, a member of the transforming growth factor beta superfamily, is a cytokine with an essential 306 role in skeletal development and mature bone remodeling, regulating both osteoblast and 307 osteoclast cell lineages.^{41,42} Gain-of-function mutations in *TGFB1* predispose to diaphyseal 308 dysplasia, and mutations in other TGF β superfamily members can cause multiple skeletal disorders 309 of varying severity.⁴³

310 Other potentially causative TGF β -related genes in the otosclerosis susceptibility loci include *RUNX2* in chromosome 3, AHSG in chromosome 8, and LTBP3 and FAM89B in chromosome 11, all of which 311 312 are associated with the expression of the respective lead variants. RUNX2 is a transcription factor regulated by TGF^{β1}-signalling via both the canonical Smad and p38 MAPK pathways and has an 313 314 essential role in osteoblast and chondrocyte differentiation.^{41,42,44} Alpha2-HS-glycoprotein/fetuin 315 (AHSG) antagonizes TGF^{β1}-signalling by binding to TGF^{β1} and TGF^β related bone morphogenic proteins (BMPs).^{45,46} It can also affect mineralization directly by inhibiting calcium phosphate 316 precipitation via formation of calcium-fetuin complexes.⁴⁷⁻⁴⁹ LTBP3 can regulate the latency and 317 activation of TGFβ1 through direct extracellular binding.⁵⁰ The nearby *FAM89B* codes for Leucine 318

repeat adapter protein 25, which may regulate TGFβ signaling by preventing the nuclear
 translocation of Smad2.⁵¹

321 In addition to signaling proteins, COL1A1 coding for the major subunit of type I collagen is a prominent candidate gene for otosclerosis.^{12,27-29,52} Mutations in *COL1A1* predispose to 322 osteogenesis imperfecta, often also characterized by hearing loss. In osteogenesis imperfecta, 323 324 similarly to carriers of truncating *MEPE* variants, increased bone turnover in the middle could occur 325 in association with general skeletal fragility. While we do not observe a strong signal for COL1A1, similarly to most examined candidate genes, we report an intronic association signal in COL4A2, 326 327 coding for a subunit of collagen IV, located in the basement membrane. Future mechanistic studies 328 could examine whether COL4A2 has a structural or signaling role in otosclerosis. COL4A2 is highly 329 conserved across species, and its mutations have been reported in a broad spectrum of organ anomalies, but we are not aware of a previous association with skeletal disorders.⁵³ Although type 330 331 IV collagens regulate BMPs in Drosophila, a similar role in humans is uncertain.⁵⁴

332 Our results highlight several genes and signaling pathways for follow-up mechanistic studies. Genetic discovery has also increasingly preceded or guided therapeutic development. Future 333 334 sequencing studies could aim to discover loss-of-function mutations within the susceptibility loci to 335 approximate the effects of therapeutic inhibition. In the case of *TGFB1*, loss-of-function mutations 336 are exceedingly rare and functional studies are needed to assess the effect of direct TGF^{β1} inhibition.²⁴ Of note, an inhibitor of BMP type I receptor kinases has been studied for the treatment 337 338 of ectopic ossification; however, in our meta-analysis, its targets (coded by ACVR1 and BMPR1A) were not significantly associated with otosclerosis.⁵⁵ Reflecting the heterogeneity of conditions 339 associated with different TGF^β superfamily genes, therapeutic intervention may need to be 340 precisely tailored to each condition.⁴¹ 341

Although we present the largest GWAS study of otosclerosis to date, our study has limitations. The identification of otosclerosis cases is based on ICD diagnoses, which we could not verify with audiometric or imaging data. However, the prevalence of stapes procedures among cases is concordant with clinical experience. As bone data are not available within the GTEx consortium, the analyses of gene expression rely on other tissues; associations in bone could differ. The physical proximity of lead variants with biologically relevant genes does not prove causation; identified and unidentified variants in the loci can exert their effects through yet unknown mechanisms.

- 349 In summary, we determine a polygenic basis to otosclerosis with 18 genome-wide significant
- 350 susceptibility loci, and shared heritability between otosclerosis and other common and rare skeletal
- 351 traits. The loci offer multiple potential avenues for understanding disease pathophysiology through
- genes involved in bone remodeling, mineralization, and basement membrane collagen composition. 352
- 353 In particular, our results highlight several TGFβ superfamily members for follow-up studies.

354 Methods

355 Cohort descriptions

We identified individuals with ICD-based otosclerosis diagnoses from three national biobank-based cohorts: The Finnish FinnGen cohort, the Estonian Biobank (EstBB) and the UK Biobank (UKBB).

358 The FinnGen data used here comprise 210,932 individuals from FinnGen Data Freeze 5 359 (https://www.finngen.fi). The data were linked by unique national personal identification numbers 360 to the national hospital discharge registry (available from 1968) and the specialist outpatient registry (available from 1998). Data comprised in FinnGen Data Freeze 5 are administered by 361 362 regional biobanks (Auria Biobank, Biobank of Central Finland, Biobank of Eastern Finland, Borealis Biobank, Helsinki Biobank, Tampere Biobank), the Blood Service Biobank, the Terveystalo Biobank, 363 364 and biobanks administered by the Finnish Institute for Health and Welfare (THL) for the following 365 studies: Botnia, Corogene, FinHealth 2017, FinIPF, FINRISK 1992–2012, GeneRisk, Health 2000, Health 2011, Kuusamo, Migraine, Super, T1D, and Twins). The FinnGen study protocol 366 367 (HUS/990/2017) was approved by the Ethics Review Board of the Hospital District of Helsinki and 368 Uusimaa.

EstBB is a population-based cohort of 200,000 participants with a rich variety of phenotypic and 369 370 health-related information collected for each individual.⁵⁶ At recruitment, participants have signed 371 a consent to allow follow-up linkage of their electronic health records (EHR), thereby providing a 372 longitudinal collection of phenotypic information. EstBB allows access to the records of the national 373 Health Insurance Fund Treatment Bills (from 2004), Tartu University Hospital (from 2008), and North 374 Estonia Medical Center (from 2005). For every participant there is information on diagnoses in ICD-375 10 coding and drug dispensing data, including drug ATC codes, prescription status and purchase date (if available). 376

UKBB comprises phenotype data from 500,000 volunteer participants from the UK population aged
between 40 and 69 years during recruitment in 2006-2010.⁵⁷ Data for all participants have been
linked with national Hospital Episode Statistics.

380 Identification of otosclerosis cases

Case status was assigned for individuals with any ICD-10 H80* code, or when available, the ICD-9 code 387 or ICD-8 code 386 (Table 1). In FinnGen, only ICD codes registered in specialty care settings were used for case definition. Stapes procedures were identified based on the Nomesco codes DDA00 (stapedotomy) and DDB00 (stapedectomy) in FinnGen and the national health insurance treatment service code 61006 (stapedotomy) in EstBB.

386 Genotyping and imputation of variants

FinnGen samples were genotyped using Illumina and Affymetrix arrays (Illumina Inc., San Diego, and Thermo Fisher Scientific, Santa Clara, CA, USA). Genotype imputation was performed using a population-specific SISu v3 imputation reference panel comprised of 3,775 whole genomes as described (https://www.protocols.io/view/genotype-imputation-workflow-v3-0-xbgfijw).

The samples from the Estonian Biobank were genotyped at the Genotyping Core Facility of the 391 392 Institute of Genomics, University of Tartu using the Global Screening Array (GSAv1.0, GSAv2.0, and 393 GSAv2.0_EST) from Illumina. Altogether 155,772 samples were genotyped and PLINK format files 394 were exported using GenomeStudio v2.0.4.⁵⁸ Individuals were excluded from the analysis if their 395 call-rate was < 95% or if the sex defined based on heterozygosity of the X chromosome did not 396 match the sex in phenotype data. Variants were excluded if the call-rate was < 95% and HWE p-397 value < 1e-4 (autosomal variants only). Variant positions were updated to genome build 37 and all alleles were switched to the TOP strand using tools and reference files provided at 398 399 https://www.well.ox.ac.uk/~wrayner/strand/. After QC the dataset contained 154,201 samples for 400 imputation. Before imputation variants with MAF<1% and indels were removed. Prephasing was done using the Eagle v2.3 software.⁵⁹ The number of conditioning haplotypes Eagle2 uses when 401 402 phasing each sample was set to: --Kpbwt=20000. Imputation was done using Beagle v.28Sep18.793 with effective population size ne=20,000.⁶⁰ An Estonian population specific imputation reference of 403 2297 WGS samples was used.⁶¹ 404

405 UKBB samples have been genotyped and imputed as described previously.⁵⁷ Additional quality 406 controls of version 3 data have been performed and publicly reported by the Pan-UKB team from 407 the Analytic & Translational Genetics Unit (ATGU) at Massachusetts General Hospital and the Broad 408 Institute of MIT and Harvard (https://pan.ukbb.broadinstitute.org. 2020). The analysis referenced 409 in this study is based on samples from 419,622 individuals with European ancestry.

410 Statistical analysis

GWAS for the individual study cohorts was performed using a generalized mixed model with the saddlepoint approximation using SAIGE v0.20, using a kinship matrix as a random effect and covariates as fixed effects.⁶² For all cohorts, variants with a minor allele frequency less than 0.1% were excluded.

415 In FinnGen, samples from individuals with non-Finnish ancestry and twin/duplicate samples were excluded, and GWAS was performed for 1,350 cases and 209,582 controls. Age, sex, 10 PCs and the 416 417 genotyping batch (for batches with at least 10 cases and controls) were used as covariates. Results were filtered to variants with imputation INFO score > 0.6. In EstBB, a GWAS was performed on 713 418 419 cases and 136,7933 controls of European ancestry including related individuals and adjusting for the 420 first 10 PCs of the genotype matrix, as well as for birth year and sex. The statistical analysis of UKBB 421 data performed has been and publicly reported by the Pan-UKB team 422 (https://pan.ukbb.broadinstitute.org. 2020). The UKBB GWAS results are reproduced here for 423 selected variants for the purpose of cross-cohort replication and inclusion in the meta-analysis.

424 Variant positions in the UKBB and EstBB summary statistics were lifted from GRCh37 to GRCh38 using the liftOver v1.12 Bioconductor R package.⁶³ To assess similarity of genetic effects between 425 426 cohorts, we used the cross-trait LD Score Regression to calculate pairwise genetic correlations (rg) based on summary statistics from each cohort.^{20,21} Summary statistics from the individual cohorts 427 428 for 13,762,819 variants present in at least two cohorts with a cross-cohort minor allele frequency > 429 0.1% and imputation INFO score > 0.7 were combined using an inverse-variance weighted fixedeffect meta-analysis with GWAMA v2.2.2.⁶⁴ The following analyses are based on summary statistics 430 431 from the meta-analysis unless otherwise specified.

432 Characterization of association loci

For the individual cohorts and meta-analysis, we merged genome-wide significant variants within 500kb of each other into association loci. The lead variants from these loci were not in LD with each other based on individual-level data from FinnGen ($r^2 < 1*10^{-4}$ for all variant pair comparisons). We annotated the lead variants by mapping their physical position to genes and consequences using the Ensembl Variant Effect Predictor (VEP) based on the GRCh38 genome build.⁶⁵ In addition, we

438 annotated all genome-wide significant variants and all variants in high LD (r>0.6) with the lead 439 variants from the meta-analysis using VEP. As the highest number of association loci was observed in FinnGen, we estimated LD in the FinnGen cohort using PLINK v1.07.^{66,67} LocusZoom was used to 440 visualize the association loci and the regions surrounding other genes of interest.⁶⁸ 441

442 **Fine-mapping**

443 Based on otosclerosis summary statistics from FinnGen, we fine-mapped all regions where the lead variant reached a p-value of $< 1*10^{-6}$ in FinnGen using FINEMAP v1.4.²⁵ We used a 3Mb window (± 444 1.5Mb) around each lead variant, and calculated LD between each variant from individual-level 445 FinnGen data. For credible sets with over 10 variants, we report those with a \geq 0.01 probability of 446 447 being causal.

448 eQTL and sQTL mapping

449 We used the GTEx v8 database (https://gtexportal.org) to map otosclerosis susceptibility variants to genes and tissues.²³ We downloaded the data for all 49 tissues, and mapped the lead variants 450 451 from the meta-analysis, as well as selected variants of interest (e.g. from candidate gene loci), to 452 eQTL (expression quantitative locus) or sQTL (splicing quantitative locus) associations using the 5% 453 false discovery rate cut-off provided by the GTEx Consortium.

454 Gene and gene set -based analyses

455 We used MAGMA v1.07 to identify genes and gene sets associated with otosclerosis based on effect estimates from the meta-analysis.⁶⁹ Variants were mapped to 18,910 genes based on their RefSNP 456 457 numbers. We performed a gene-based analysis using the default SNPwise-mean model and a 458 Bonferroni-corrected *p*-value threshold ($\alpha = 0.05/18,910$). Based on the results from the gene-based analysis, we then performed a competitive gene set based analysis using 10,182 GO term based 459 460 gene sets downloaded from the Molecular Signature Database v7.1, using a Bonferroni-corrected *p*-value threshold ($\alpha = 0.05/10,182$).⁷⁰ 461

462 Phenome-wide association analyses and genetic correlations

463 We examined the pleiotropic effects of lead variants based on phenome-wide association studies in 464 FinnGen and UKBB. In FinnGen, GWAS was performed for 2,925 registry-based disease endpoints similarly to the GWAS for otosclerosis. The study participants were linked with national registries 465 covering the whole population for hospital discharges (data available since 1968), deaths (1969–), 466 outpatient specialist appointments (1998–), cancers (1953–), and medication reimbursements 467 (1995–). Disease endpoints were collated based on International Classification of Diseases (ICD) 468 codes (revisions 8–10), International Classification of Diseases for Oncology (ICD-O) third edition 469 470 codes, NOMESCO procedure codes, Finnish-specific Social Insurance Institute (KELA) drug 471 reimbursement codes, and drug-specific ATC-codes. In addition, specific clinical endpoints combining relevant comorbidities and exclusion criteria have been curated in coordination with 472 clinical expert groups. Currently available FinnGen phenotype definitions are available online at 473 474 https://www.finngen.fi/en/researchers/clinical-endpoints.

475 For UKBB, we downloaded publicly available association results for 2419 phenotypes including 476 diseases and anthropometric traits (http://www.nealelab.is/uk-biobank & 477 http://pheweb.sph.umich.edu:5000). Bonferroni-corrected p-value thresholds were used for each cohort (α = 0.05/2925 for FinnGen and α = 0.05/2419 for UKBB). Additionally, using the GWAS 478 479 Catalog database (accessed on 22 April 2020), we performed a lookup of previously published association results for all variants significantly associated with otosclerosis in the meta-analysis.³³ 480

For three frequently occurring coassociations (height, bone mineral density (BMD), and fracture risk, we estimated the genetic correlations of each trait with otosclerosis using LD Score Regression.^{20,21} We used summary statistics from recently published large GWA studies: the GWAS meta-analysis of height in approximately 700,000 individuals by the GIANT Consortium, and the GWAS of ultrasound-quantified heel BMD and fracture risk in approximately 460,000 UKBB participants by the GEFOS Consortium.^{20,35,36}

Acknowledgements 487

488 This research has been conducted using the UK Biobank Resource under Application Number 22627. 489 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office 490 of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and 491 NINDS. The data used for the gene expression analyses described in this manuscript were obtained 492 from the GTEx Portal in July 2020. We thank the Pan UKBB analysis team from the Analytic & 493 Translational Genetics Unit (ATGU) at Massachusetts General Hospital and the Broad Institute of 494 MIT and Harvard for making UKBB summary statistics publicly available. We thank all study 495 participants for their generous contributions to the biobanks.

medRxiv preprint doi: https://doi.org/10.1101/2020.11.15.20227868; this version posted November 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

496 **References**

497 Quesnel, A. M., Ishai, R. & McKenna, M. J. Otosclerosis: Temporal Bone Pathology. 1 498 Otolaryngol. Clin. North Am. 51, 291-303, doi:10.1016/j.otc.2017.11.001 (2018). 499 Babcock, T. A. & Liu, X. Z. Otosclerosis: From Genetics to Molecular Biology. Otolaryngol. 2 500 *Clin. North Am.* **51**, 305-318, doi:10.1016/j.otc.2017.11.002 (2018). 501 Ramaswamy, A. T. & Lustig, L. R. Revision Surgery for Otosclerosis. Otolaryngol. Clin. North 3 502 Am. 51, 463-474, doi:10.1016/j.otc.2017.11.014 (2018). 503 Declau, F. et al. Prevalence of otosclerosis in an unselected series of temporal bones. 4 504 Otology and Neurotology **22**, 596-602, doi:10.1097/00129492-200109000-00006 (2001). 505 5 Declau, F. et al. Prevalence of histologic otosclerosis: an unbiased temporal bone study in 506 Caucasians. Adv. Otorhinolaryngol. 65, 6-16, doi:10.1159/000098663 (2007). 507 6 House, H. P., Hansen, M. R., Al Dakhail, A. A. & House, J. W. Stapedectomy versus 508 stapedotomy: comparison of results with long-term follow-up. Laryngoscope 112, 2046-509 2050, doi:10.1097/00005537-200211000-00025 (2002). 510 7 Del Bo, M., Zaghis, A. & Ambrosetti, U. Some observations concerning 200 stapedectomies: 511 fifteen years postoperatively. Laryngoscope 97, 1211-1213, doi:10.1288/00005537-512 198710000-00017 (1987). 513 Cawthorne, T. Otosclerosis. J. Laryngol. Otol. 69, 437-456, 8 514 doi:10.1017/s0022215100050933 (1955). 515 9 Morrison, A. W. Genetic factors in otosclerosis. Ann. R. Coll. Surg. Engl. 41, 202-237 (1967). 516 10 Moumoulidis, I., Axon, P., Baguley, D. & Reid, E. A review on the genetics of otosclerosis. 517 *Clin. Otolaryngol.* **32**, 239-247, doi:10.1111/j.1365-2273.2007.01475.x (2007). 518 Larsson, A. Otosclerosis. A genetic and clinical study. Acta Otolaryngol. Suppl. 154, 1-86 11 519 (1960).Bittermann, A. J. et al. An introduction of genetics in otosclerosis: a systematic review. 520 12 521 Otolaryngol. Head Neck Surg. 150, 34-39, doi:10.1177/0194599813509951 (2014). 522 Valgaeren, H. et al. Insufficient evidence for a role of SERPINF1 in otosclerosis. Mol. Genet. 13 Genomics 294, 1001-1006, doi:10.1007/s00438-019-01558-8 (2019). 523 524 Schrauwen, I. et al. A Genome-wide Analysis Identifies Genetic Variants in the RELN Gene 14 525 Associated with Otosclerosis. The American Journal of Human Genetics 84, 328-338, 526 doi:https://doi.org/10.1016/j.ajhg.2009.01.023 (2009). 527 15 Mowat, A. J. et al. Evidence of distinct RELN and TGFB1 genetic associations in familial and 528 non-familial otosclerosis in a British population. Hum. Genet. 137, 357-363, 529 doi:10.1007/s00439-018-1889-9 (2018). 530 16 Priyadarshi, S., Hansdah, K., Ray, C. S., Biswal, N. C. & Ramchander, P. V. Otosclerosis 531 Associated with a De Novo Mutation -832G > A in the TGFB1 Gene Promoter Causing a 532 Decreased Expression Level. Sci. Rep. 6, 29572, doi:10.1038/srep29572 (2016). 533 Priyadarshi, S. et al. Genetic association and gene expression profiles of TGFB1 and the 17 534 contribution of TGFB1 to otosclerosis susceptibility. J. Bone Miner. Res. 28, 2490-2497, 535 doi:10.1002/jbmr.1991 (2013). 536 Thys, M. et al. Detection of Rare Nonsynonymous Variants in TGFB1 in Otosclerosis 18 537 Patients. Ann. Hum. Genet. 73, 171-175, doi:10.1111/j.1469-1809.2009.00505.x (2009). 538 19 Schrauwen, I. et al. Association of Bone Morphogenetic Proteins With Otosclerosis. J. Bone 539 Miner. Res. 23, 507-516, doi:doi:10.1359/jbmr.071112 (2008). 540 Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. 20 541 Nat. Genet. 47, 1236-1241, doi:10.1038/ng.3406 (2015).

542 21 Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity 543 in genome-wide association studies. Nat. Genet. 47, 291-295, doi:10.1038/ng.3211 (2015). 544 22 Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236-1241, doi:10.1038/ng.3406 (2015). 545 546 Aguet, F. et al. The GTEx Consortium atlas of genetic regulatory effects across human 23 547 tissues. bioRxiv, 787903, doi:10.1101/787903 (2019). 548 24 Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 549 141,456 humans. Nature 581, 434-443, doi:10.1038/s41586-020-2308-7 (2020). 550 25 Benner, C. et al. FINEMAP: efficient variable selection using summary data from genome-551 wide association studies. Bioinformatics 32, 1493-1501, 552 doi:10.1093/bioinformatics/btw018 (2016). 553 26 Massagué, J. TGFβ signalling in context. *Nature Reviews Molecular Cell Biology* **13**, 616-630, 554 doi:10.1038/nrm3434 (2012). 555 Schrauwen, I. et al. COL1A1 association and otosclerosis: A meta-analysis. American 27 556 Journal of Medical Genetics Part A 158A, 1066-1070, doi:10.1002/ajmg.a.35276 (2012). 557 Khalfallah, A. et al. Association of COL1A1 and TGFB1 Polymorphisms with Otosclerosis in a 28 558 Tunisian Population. Ann. Hum. Genet. 75, 598-604, doi:10.1111/j.1469-1809.2011.00665.x 559 (2011). 560 29 Chen, W. et al. Single-nucleotide polymorphisms in the COL1A1 regulatory regions are associated with otosclerosis. Clin. Genet. 71, 406-414, doi:10.1111/j.1399-561 562 0004.2007.00794.x (2007). 563 Ziff, J. L. et al. Mutations and altered expression of SERPINF1 in patients with familial 30 564 otosclerosis. Hum. Mol. Genet. 25, 2393-2403, doi:10.1093/hmg/ddw106 (2016). 565 31 Schrauwen, I. et al. Association of bone morphogenetic proteins with otosclerosis. J. Bone Miner. Res. 23, 507-516, doi:10.1359/jbmr.071112 (2008). 566 567 Pauw, R. J. et al. Phenotype description of a Dutch otosclerosis family with suggestive 32 568 linkage to OTSC7. American Journal of Medical Genetics Part A 143A, 1613-1622, 569 doi:10.1002/ajmg.a.31807 (2007). 570 Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association 33 571 studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005-d1012, 572 doi:10.1093/nar/gky1120 (2019). 573 Nakajima, M. et al. A genome-wide association study identifies susceptibility loci for 34 574 ossification of the posterior longitudinal ligament of the spine. Nat. Genet. 46, 1012-1016, 575 doi:10.1038/ng.3045 (2014). 576 Yengo, L. et al. Meta-analysis of genome-wide association studies for height and body mass 35 577 index in ~700000 individuals of European ancestry. Hum. Mol. Genet. 27, 3641-3649, 578 doi:10.1093/hmg/ddy271 (2018). 579 Morris, J. A. et al. An atlas of genetic influences on osteoporosis in humans and mice. Nat. 36 580 Genet. 51, 258-266, doi:10.1038/s41588-018-0302-x (2019). 581 Rudic, M. et al. The pathophysiology of otosclerosis: Review of current research. Hear. Res. 37 582 330, 51-56, doi:10.1016/j.heares.2015.07.014 (2015). 583 Schrauwen, I. et al. Variants affecting diverse domains of MEPE are associated with two 38 584 distinct bone disorders, a craniofacial bone defect and otosclerosis. Genet. Med. 21, 1199-585 1208, doi:10.1038/s41436-018-0300-5 (2019). 586 39 Van Hout, C. V. et al. Whole exome sequencing and characterization of coding variation in 587 49,960 individuals in the UK Biobank. *bioRxiv*, 572347, doi:10.1101/572347 (2019).

- 588 40 Schrauwen, I. et al. A genome-wide analysis identifies genetic variants in the RELN gene 589 associated with otosclerosis. Am. J. Hum. Genet. 84, 328-338, 590 doi:10.1016/j.ajhg.2009.01.023 (2009).
- 591 Wu, M., Chen, G. & Li, Y.-P. TGF-β and BMP signaling in osteoblast, skeletal development, 41 592 and bone formation, homeostasis and disease. Bone Research 4, 16009, 593 doi:10.1038/boneres.2016.9 (2016).
- 594 42 Crane, J. L. & Cao, X. Bone marrow mesenchymal stem cells and TGF-β signaling in bone 595 remodeling. The Journal of clinical investigation 124, 466-472, doi:10.1172/JCI70050 596 (2014).
- 597 43 Kinoshita, A. et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann 598 disease. Nat. Genet. 26, 19-20, doi:10.1038/79128 (2000).
- 599 44 Komori, T. Regulation of Proliferation, Differentiation and Functions of Osteoblasts by 600 Runx2. Int. J. Mol. Sci. 20, doi:10.3390/ijms20071694 (2019).
- 601 Demetriou, M., Binkert, C., Sukhu, B., Tenenbaum, H. C. & Dennis, J. W. Fetuin/alpha2-HS 45 602 glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine 603 antagonist. J. Biol. Chem. 271, 12755-12761, doi:10.1074/jbc.271.22.12755 (1996).
- 604 46 Szweras, M. et al. alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone 605 morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J. 606 Biol. Chem. 277, 19991-19997, doi:10.1074/jbc.M112234200 (2002).
- 607 Schinke, T. et al. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite 47 608 formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and 609 calcium homeostasis. J. Biol. Chem. 271, 20789-20796, doi:10.1074/jbc.271.34.20789 610 (1996).
- 611 48 Heiss, A. et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-612 A. Formation of colloidal calciprotein particles. J. Biol. Chem. 278, 13333-13341, doi:10.1074/jbc.M210868200 (2003). 613
- 614 Price, P. A. & Lim, J. E. The inhibition of calcium phosphate precipitation by fetuin is 49 615 accompanied by the formation of a fetuin-mineral complex. J. Biol. Chem. 278, 22144-616 22152, doi:10.1074/jbc.M300744200 (2003).
- 617 Robertson, I. B. et al. Latent TGF-β-binding proteins. Matrix Biol. 47, 44-53, 50 618 doi:10.1016/j.matbio.2015.05.005 (2015).
- 619 Kokura, K. et al. The Ski-binding Protein C184M Negatively Regulates Tumor Growth 51 620 Factor-β Signaling by Sequestering the Smad Proteins in the Cytoplasm. J. Biol. Chem. 278, 621 20133-20139, doi:10.1074/jbc.M210855200 (2003).
- 622 McKenna, M. J., Kristiansen, A. G., Bartley, M. L., Rogus, J. J. & Haines, J. L. Association of 52 623 COL1A1 and otosclerosis: evidence for a shared genetic etiology with mild osteogenesis 624 imperfecta. Am. J. Otol. 19, 604-610 (1998).
- 625 Meuwissen, M. E. et al. The expanding phenotype of COL4A1 and COL4A2 mutations: 53 626 clinical data on 13 newly identified families and a review of the literature. Genet. Med. 17, 627 843-853, doi:10.1038/gim.2014.210 (2015).
- 628 Wang, X., Harris, R. E., Bayston, L. J. & Ashe, H. L. Type IV collagens regulate BMP signalling 54 629 in Drosophila. Nature 455, 72-77, doi:10.1038/nature07214 (2008).
- 630 Yu, P. B. et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. 55 631 Nat. Med. 14, 1363-1369, doi:10.1038/nm.1888 (2008).
- 632 56 Leitsalu, L., Alavere, H., Tammesoo, M. L., Leego, E. & Metspalu, A. Linking a population 633 biobank with national health registries-the estonian experience. Journal of personalized 634 medicine 5, 96-106, doi:10.3390/jpm5020096 (2015).

- 635 57 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. 636 Nature 562, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- 637 Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer 58 638 datasets. GigaScience 4, 7, doi:10.1186/s13742-015-0047-8 (2015).
- 639 Loh, P. R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. 59 640 Nat. Genet. 48, 1443-1448, doi:10.1038/ng.3679 (2016).
- Browning, S. R. & Browning, B. L. Rapid and accurate haplotype phasing and missing-data 641 60 inference for whole-genome association studies by use of localized haplotype clustering. 642 Am. J. Hum. Genet. 81, 1084-1097, doi:10.1086/521987 (2007). 643
- Mitt, M. et al. Improved imputation accuracy of rare and low-frequency variants using 644 61 645 population-specific high-coverage WGS-based imputation reference panel. Eur. J. Hum. 646 Genet. 25, 869-876, doi:10.1038/ejhg.2017.51 (2017).
- 647 62 Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in 648 large-scale genetic association studies. Nat. Genet. 50, 1335-1341, doi:10.1038/s41588-649 018-0184-y (2018).
- Bioconductor Package Maintainer (2020). liftOver: Changing genomic coordinate systems 650 63 with rtracklayer::liftOver. R package version 1.12.0, 651
- https://www.bioconductor.org/help/workflows/liftOver/. 652
- Mägi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis. 653 64 654 BMC Bioinformatics 11, 288, doi:10.1186/1471-2105-11-288 (2010).
- 655 McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122, 65 656 doi:10.1186/s13059-016-0974-4 (2016).
- 657 66 PLINK v1.07. URL: http://pngu.mgh.harvard.edu/purcell/plink/.
- Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based 658 67 linkage analyses. Am. J. Hum. Genet. 81, 559-575, doi:10.1086/519795 (2007). 659
- Pruim, R. J. et al. LocusZoom: regional visualization of genome-wide association scan 660 68 results. Bioinformatics (Oxford, England) 26, 2336-2337, 661
- doi:10.1093/bioinformatics/btq419 (2010). 662
- 663 69 de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, e1004219, 664
- 665 doi:10.1371/journal.pcbi.1004219 (2015).
- 666 70 Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set 667 collection. Cell systems 1, 417-425, doi:10.1016/j.cels.2015.12.004 (2015).

Figures and tables 669





672 Figure 1. Meta-analysis of the genome-wide association studies of Otosclerosis in FinnGen, EstBB and UKBB. In the Manhattan plot, chromosomal positions are indicated on the x-axis and -log₁₀(p-673 674 value) is presented on the y-axis for each variant. Results are presented for a fixed-effect metaanalysis of effect estimates from GWASs in the three cohorts, including a total of 2,413 cases and 675 676 762,382 controls. The included variants were present in at least two cohorts with a cross-cohort minor allele frequency > 0.1% and imputation INFO score > 0.7. Eighteen loci reached genome-wide 677 significance ($p < 5*10^{-8}$, marked by the dashed line). The loci are annotated by the names of the 678 679 genes nearest to the lead variants.

681 Table 1. ICD and procedure codes corresponding to otosclerosis in each study cohort. Stapes

682 procedures were identified based on the Nomesco codes DDA00 (stapedotomy) and DDB00

(stapedectomy) in FinnGen and the national health insurance treatment service code 61006 683

- (stapedotomy) in EstBB. 684
- 685

Classification	Code	Definition	FinnGen	EstBB	UKBB
	H80	Otosclerosis (any)		256	318
ICD-10	H80.0	Involving oval window, nonobliterative	655	246	10
	H80.1	Involving oval window, obliterative	185	63	3
	H80.2	Cochlear	45	32	3
	H80.8	Other	133	95	6
	H80.9	Unspecified	628	379	301
ICD-9	387	Otosclerosis (any)	272		36
ICD-8	386	Otosclerosis (any)	284		
Procedures		Stapedotomy	458	161	
Procedures		Stapedectomy	113		
Total cases			1350	713	350
Total controls			209582	136793	416007
Prevalence (%)			0.64	0.52	0.08

- Table 2. Lead variants for significant association loci in the meta-analysis of otosclerosis. Data (in 687
- 688 cursive) are also presented for the rs753138805 variant in MEPE, observed only in FinnGen and not
- included in the meta-analysis. Chr = chromosome, EA = effect allele, EAF = effect allele frequency, 689
- *NEA* = non-effect allele, *OR* = odds ratio, *CI* = confidence interval. 690

						Nearest			
Rsid	Chr	Position	EA	NEA	EAF	Gene	Consequence	OR (95% CI)	P-value
rs4876361	8	116554149	А	G	0.71	EIF3H	Intergenic	0.73 (0.68-0.78)	7.2*10 ⁻²²
rs8070086	17	68682159	А	G	0.24	LINC01482 /	Intronic /	1.39 (1.29-1.49)	1.8*10 ⁻¹⁸
						FAM20A	Intergenic		
rs1951391	14	103431976	С	Т	0.33	MARK3	Intronic	1.38 (1.28-1.49)	7.0*10 ⁻¹⁷
rs947091	10	30765257	А	G	0.42	ZNF438	Regulatory Region	0.77 (0.73-0.82)	9.2*10 ⁻¹⁷
rs67924081	11	65575510	G	А	0.23	EHBP1L1	Upstream Gene	0.72 (0.67-0.78)	2.5*10 ⁻¹⁶
rs39352	7	103827282	Т	G	0.41	RELN	Intronic	1.24 (1.17-1.32)	1.8*10 ⁻¹²
rs9559805	13	110462733	А	С	0.48	COL4A2,	Synonymous	0.82 (0.77-0.87)	3.4*10 ⁻¹¹
						COL4A2-AS2			
rs10943838	6	81969549	С	G	0.61	IBTK	Upstream Gene	0.82 (0.77-0.87)	8.4*10 ⁻¹¹
rs3922616	16	55008491	С	А	0.43	IRX5	Intergenic	1.21 (1.14-1.29)	1.9*10 ⁻¹⁰
rs9469583	6	33749993	С	Т	0.58	IP6K3	Upstream Gene	1.22 (1.15-1.3)	2.1*10 ⁻¹⁰
rs13192457	6	44887654	А	С	0.44	SUPT3H	Intronic	1.25 (1.17-1.34)	2.3*10 ⁻¹⁰
rs67284550	16	1480948	Т	С	0.42	PTX4	Downstream Gene	1.2 (1.13-1.28)	7.6*10 ⁻¹⁰
rs4917	3	186619924	С	Т	0.64	AHSG	Missense	0.83 (0.78-0.88)	2.3*10 ⁻⁹
rs6066131	20	46941020	С	Т	0.45	EYA2	Intronic	1.19 (1.12-1.26)	4.0*10 ⁻⁹
rs7683897	4	87888898	А	G	0.41	MEPE	Intergenic	1.19 (1.12-1.26)	4.3*10 ⁻⁹
rs753138805	4	87845066	G	GGAAA	0.0032	MEPE	Frameshift	18.9 (8.05-44.4)	1.5*10 ⁻¹¹
rs8105161	19	41333726	С	Т	0.16	TGFB1	Intronic	0.8 (0.74-0.86)	1.8*10 ⁻⁸
rs80339979	9	99889430	G	GA	0.64	STX17-AS1	Intronic	1.19 (1.12-1.26)	1.9*10 ⁻⁸
rs9397842	6	155810724	G	Т	0.78	NOX3	Intergenic	0.79 (0.73-0.86)	4.7*10 ⁻⁸

691

- Table 3: Biological functions of genes in selected association loci. In 13 association loci, genes 693
- 694 implicated in bone metabolism are in close proximity with the lead variant or associated with the
- expression of the lead variant. eQTL = expression quantitative trait locus, sQTL = splicing 695
- quantitative trait locus. References to individual studies are listed in Supplementary Data 15. 696
- 697
- 698

----- Table shown on next page ------

Rsid	Chr	Position	Nearest Gene	Consequence	Biological role(s) of selected gene(s) in locus	Severe skeletal phenotypes associated with variants in loci (ClinVar & GWAS Catalog)
rs4876361	8	116554149	EIF3H	Intergenic Variant	TRPS1 (750kb from rs4876361): Trichorhinophalangeal syndrome type I. TNFRSF11B (2.3Mb from rs4876361) : Osteoprotegerin, inhibitor of osteoclast differentiation and function.	rs13279799: Ossification of the posterior longitudinal ligament of the spine. <i>TRPS1</i> : Trichorhinophalangeal syndrome types I and III, Langer- Giedion syndrome
rs1951391	14	103431976	MARK3	Intron Variant	MARK3 (eQTL and sQTL): Potential regulator of BMD. CKB (eQTL and sQTL): Regulator of the bone-resorbing function of osteoclasts.	
rs67924081	11	65575510	EHBP1L1	Upstream Gene Variant	<i>LTBP3</i> (eQTL and sQTL): Latent Transforming Growth Factor Beta Binding Protein 3 (LTBP3), a component of the extracellular matrix. Regulates TGFβ activity via extracellular binding. <i>FAM89B</i> (eQTL): Regulates TGFβ signalling by preventing the nuclear translocation of Smad2. <i>NEAT1</i> (eQTL): Long noncoding RNA. Overexpression has been reported both in osteoporosis through ostoclastogenesis stimulation and in osteosarcoma as a stimulator of cell proliferation.	LTBP3: Acromicric dysplasia, Brachyolmia-amelogenesis imperfecta syndrome, Geleophysic dysplasia. BANF1 (sQTL) : Nestor- Guillermo progeria syndrome
rs9559805	13	110462733	COL4A2, COL4A2-AS2	Synonymous Variant	COL4A2 (eQTL): Alpha-2 chain of basement membrane collagen.	
rs10943838	6	81969549	ΙΒΤΚ	Upstream Gene Variant	TPBG (eQTL): Binds osteoclast-derived collagen triple helix repeat containing 1, a stimulator of osteoblast differentiation.	
rs3922616	16	55008491	IRX5	Intergenic Variant	<i>IRX5</i> : Regulator of mineralization in cranial bones.	
rs9469583	6	33749993	IP6K3	Upstream Gene Variant	ITPR3 (eQTL & sQTL): Regulator of osteoclastogenesis; mediates the activation of IRE1 α via calcium infux.	IRX5: Hamamy syndrome (with features including skeletal abnormalities, short stature and hearing loss)
rs13192457	6	44887654	SUPT3H	Intron Variant	RUNX2 (sQTL): Transcription factor, regulator of osteoblast and chondrocyte differentiation. RUNX2 and SUPT3H show synteny across several species and the SUPT3H promoter is a potential regulator of the bone-specific Runx2-P1 promoter.	RUNX2 : Metaphyseal dysplasia with maxillary hypoplasia and brachydactyly, cleidocranial dysostosis
rs67284550	16	1480948	PTX4	Downstream Gene Variant	CLCN7 (eQTL and sQTL): Regulator of osteoblast function.	CLCN7: Osteopetrosis (several types)
rs4917	3	186619924	AHSG	Missense Variant	AHSG (sQTL): Binds to TGFβ1 and BMPs. Regulator of mineralization through inhibition of calcium phospate precipitation. AHSG knockout mice exhibit increased bone formation with age and ectopic bone formation in response to TGFβ1/BMP signalling.	
rs7683897	4	87888898	MEPE	Intergenic Variant	MEPE : Candidate gene for otosclerosis. Regulator of osteoclast differentiation and mineralization. SPP1 (eQTL): Osteopontin, bone matrix protein implicated in bone remodeling and osteotropic cancers. PKD2 (eQTL): PKD2 deficiency is associated with reduced expression of Runx2 and impaired osteoblastic differentiation in mouse bone.	
rs8105161	19	41333726	TGFB1	Intron Variant	TGFB1 (eQTL and sQTL): Candidate gene for otosclerosis. Essential cytokine for skeletal development and bone remodeling. Regulator of osteoblast and osteoclast cell lineages. Gain-of-function mutations predispose to Camurati- Engelman disease.	TGFB1 : Diaphyseal dysplasia